Get to know our clinical trials
Clinical trial to evaluate the safety, pharmacokinetics and activity of RO7656594 in patients with advanced or metastatic prostate cancer
THE AIM OF THIS STUDY IS TO EVALUATE RO7656594 AT DIFFERENT DOSES TO DETERMINE IF IT IS SAFE AND HOW IT IS PROCESSED BY YOUR BODY. THE STUDY CONSISTS OF TWO PARTS: A DOSE-FINDING STEP AND A SCALE-UP STEP.
Technical Summary
- PHASE I OPEN-LABEL, MULTICENTER, STEP-UP, DOSE-ESCALATION, PHASE I STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF RO7656594 IN PATIENTS WITH ADVANCED OR METASTATIC PROSTATE CANCER
- Code EudraCT: 2023-504013-68-00
- Protocol number: GO44537
- Promoter: Genentech, Inc.
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.